Troponin T mutations and Sudden Cardiac Death
肌钙蛋白 T 突变与心源性猝死
基本信息
- 批准号:6942707
- 负责人:
- 金额:$ 20.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-01 至 2005-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Familial Hypertrophic Cardiomyopathy (FHC) is an autosomal-dominant disease resulting from mutations in genes encoding cardiac contractile proteins, and an important cause of Sudden Cardiac Death (SCD). Genotype/phenotype correlation studies suggest that the prognostic significance of most mutations is related to the degree of cardiac hypertrophy and fibrosis. An exception are several Troponin T (TnT) mutations, which confer a high risk of SCD even in absence of significant cardiac hypertrophy and fibrosis.In vitro studies suggest that these TnT mutations all increase myofilament Ca 2+ sensitivity. To investigate if an increased Ca 2+ sensitivity itself could be pro-arrhythmic, an animal model without the confounding fibrosis and/or hypertrophy would be ideal. We recently generated such a model by transgenic expression of mutant human TnT (179N), which resulted in increased myofilament Ca 2+ sensitivity and lack of cardiac hypertrophy and fibrosis. Our preliminary experiments on single cells show decreased Ca 2+ transients with slower decay rates, and elevated diastolic (Ca2+)i in response to beta-adrenergic receptor agonists. Isolated perfused hearts show a high incidence of ventricular arrhythmias, particularly at higher (Ca)o, associated with afterdepolarizations and altered ventricular action potential waveform. Thus we hypothesize that increased myofilament Ca 2+ sensitivity changes intracellular Ca 2+ signaling and contributes independently to development of afterdepolarizations and ventricular arrhythmias, leading to sudden cardiac death. The alternate hypothesis is that other factors than myofilament Ca 2+ sensitivity (i.e., alterations of Ca 2 + signaling without changes in myofilament Ca 2+ sensitivity) contribute to arrhythmias related to TnT mutations. To address the alternate hypothesis, we will examine a transgenic model that expresses a TnT mutation (R278C), which does NOT change myofilament Ca 2+ sensitivity. We will use the Tg-179N and Tg-R278C transgenic models to test these hypotheses from the molecular to the organ level, Each SPECIFIC AIM will independently test potential mechanistic links between changes in myofilament Ca 2+ sensitivity, in cellular Ca 2+ signaling, and in whole heart electrophysiology that may lead to ventricular arrhythmias. If validated by this research, the proposed mechanism of arrhythmogenesis may be applicable to other FHC mutations and diseases that increase myofilament Ca 2+ sensitivity.
描述(由申请人提供):家族性肥厚性心肌病(FHC)是一种常染色体显性遗传疾病,由编码心脏收缩蛋白的基因突变引起,是心脏性猝死(SCD)的重要原因。基因型/表型相关性研究表明,大多数突变的预后意义与心脏肥大和纤维化的程度有关。 肌钙蛋白T(TnT)突变是一个例外,即使没有明显的心肌肥厚和纤维化,也会增加SCD的风险,体外研究表明这些TnT突变都增加了肌丝Ca 2+敏感性。 为了研究Ca 2+敏感性增加本身是否可能是促肾上腺皮质激素的,理想的是没有混杂纤维化和/或肥大的动物模型。 我们最近通过转基因表达突变型人TnT(179 N)建立了这样一个模型,该突变型人TnT(179 N)导致肌丝Ca 2+敏感性增加,而心肌肥厚和纤维化消失。 我们对单个细胞的初步实验显示,β-肾上腺素能受体激动剂可降低Ca 2+瞬变,衰减速率较慢,并升高舒张期(Ca 2+)i。 离体心脏灌注显示室性心律失常的高发生率,特别是在高(Ca)o时,与后除极和心室动作电位波形改变有关。 因此,我们推测肌丝Ca 2+敏感性的增加改变了细胞内Ca 2+信号传导,并独立地促进了后除极和室性心律失常的发展,导致心源性猝死。 另一种假设是,除了肌丝Ca 2+敏感性之外的其他因素(即,Ca 2 +信号传导的改变而不改变肌丝Ca 2+敏感性)导致与TnT突变相关的心律失常。 为了解决替代假设,我们将检查一个转基因模型,表达一个TnT突变(R278 C),这不会改变肌丝Ca 2+敏感性。 我们将使用Tg-179 N和Tg-R278 C转基因模型从分子到器官水平来检验这些假设。每个特定的目的将独立地检验肌丝Ca 2+敏感性、细胞Ca 2+信号传导和可能导致室性心律失常的整个心脏电生理学变化之间的潜在机制联系。 如果这项研究得到证实,所提出的发病机制可能适用于其他FHC突变和疾病,增加肌丝钙敏感性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bjorn C Knollmann其他文献
Bjorn C Knollmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bjorn C Knollmann', 18)}}的其他基金
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
- 批准号:
10605187 - 财政年份:2019
- 资助金额:
$ 20.26万 - 项目类别:
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
- 批准号:
9888412 - 财政年份:2019
- 资助金额:
$ 20.26万 - 项目类别:
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
寻找基于机制的心律失常治疗方法
- 批准号:
10375446 - 财政年份:2019
- 资助金额:
$ 20.26万 - 项目类别:
Training Program in Ion Channel and Transporter Biology
离子通道和转运生物学培训计划
- 批准号:
9403769 - 财政年份:2017
- 资助金额:
$ 20.26万 - 项目类别:
Toward a Mechanism-Based Approach to Treating Atrial Fibrillation
寻找基于机制的心房颤动治疗方法
- 批准号:
9248413 - 财政年份:2015
- 资助金额:
$ 20.26万 - 项目类别:
Toward a Mechanism-Based Approach to Treating Atrial Fibrillation
寻找基于机制的心房颤动治疗方法
- 批准号:
9068340 - 财政年份:2015
- 资助金额:
$ 20.26万 - 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
- 批准号:
7251084 - 财政年份:2007
- 资助金额:
$ 20.26万 - 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
- 批准号:
7407567 - 财政年份:2007
- 资助金额:
$ 20.26万 - 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
- 批准号:
8245329 - 财政年份:2007
- 资助金额:
$ 20.26万 - 项目类别:
Calsequestrin in Ventricular Arrhythmia and Sudden Death
Calsequestrin 治疗室性心律失常和猝死
- 批准号:
7790765 - 财政年份:2007
- 资助金额:
$ 20.26万 - 项目类别:
相似海外基金
The Role of Ethnic Racial Discrimination on the Development of Anxious Hypervigilance in Latina Youth
民族种族歧视对拉丁裔青少年焦虑过度警觉的影响
- 批准号:
10752122 - 财政年份:2024
- 资助金额:
$ 20.26万 - 项目类别:
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
- 批准号:
495592 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
- 批准号:
23K14885 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Antiarrhythmic mechanisms of chronic vagal nerve stimulation in sympathetic neurons
交感神经元慢性迷走神经刺激的抗心律失常机制
- 批准号:
10635151 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Bioelectric monitoring and neuromodulation of the heart
心脏的生物电监测和神经调节
- 批准号:
10655997 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Biobehavioral Intervention to Reduce PTSD Symptoms After an ICD Shock
生物行为干预可减少 ICD 电击后的 PTSD 症状
- 批准号:
10722157 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Intraoperative Pulsed Field Ablation and Lesion Assessment System
术中脉冲场消融和病变评估系统
- 批准号:
10762116 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Soft robotic sensor arrays for fast and efficient mapping of cardiac arrhythmias.
软机器人传感器阵列可快速有效地绘制心律失常图。
- 批准号:
10760164 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
Optogenetic silencing to achieve antiarrhythmic effect of renal denervation in chronic heart failure
光遗传学沉默实现肾去神经支配慢性心力衰竭的抗心律失常作用
- 批准号:
10714486 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:
A full spectrum rational approach to identify antiarrhythmic agents targeting IKs Channels
识别针对 IK 通道的抗心律失常药物的全谱理性方法
- 批准号:
10734513 - 财政年份:2023
- 资助金额:
$ 20.26万 - 项目类别:














{{item.name}}会员




